Trial Profile

An Outpatient, Randomized, Double-Blinded, Placebo-Controlled, Cross-Over Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Apr 2025 Status changed from planning to not yet recruiting.
20 Mar 2025 According to an ARS Pharmaceuticals media release, company plans to initiate a Phase 2b clinical trial in the second quarter of 2025 and the trial is expected to enroll patients in the U.S. and Europe, with topline data anticipated in early 2026.
13 Nov 2024 According to an ARS Pharmaceuticals media release, the Phase 2b trial is expected to begin in early 2025, followed by a potential single pivotal efficacy trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com